PACB - Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
As of May 15, 2026: spot at $1.13, ATM IV 79.4%, net GEX $19.2K.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Market Cap
- $394.5M
- Beta
- 2.40
- 52-Week Range
- 0.85-2.73
- CEO
- Christian O. Henry
- Employees
- 575
- IPO Date
- Oct 27, 2010
- Exchange
- NASDAQ
What PACB Looks Like to Options Traders Today
IV rank of 15.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($19.2K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.222) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The PACB overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked PACB overview questions
- What is PACB?
- PACB is the ticker symbol for Pacific Biosciences of California, Inc., a listed security. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Listed on NASDAQ. PACB is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the PACB options snapshot look like today?
- As of May 15, 2026, the PACB options snapshot shows spot at $1.13, ATM IV 79.4%, IV rank 15.1%, net GEX $19.2K, expected move 22.76%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are PACB's key statistics?
- Pacific Biosciences of California, Inc. (PACB) carries a market capitalization of $394.5M, beta of 2.40 relative to the broader market, 52-week range of 0.85-2.73. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does PACB belong to?
- Pacific Biosciences of California, Inc. operates in the Healthcare sector, in the Medical - Devices industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare PACB's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the PACB data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).